There are 2789 resources available
391MO - Impact of diabetes and metformin use on recurrence and outcome in early colon cancer (CC) patients: A pooled analysis of 3 adjuvant trials
Presenter: Elisabeth Bergen
Session: Mini oral session - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
1151MO - Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase II trial
Presenter: Marie Wislez
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1732MO - Pembrolizumab and nintedanib for patients with advanced mesothelioma
Presenter: François-Xavier Danlos
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA43 - GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase III study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT)
Presenter: Yi-Long Wu
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1171MO - PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Presenter: Nicolas Girard
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA61 - Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study
Presenter: Luis Paz-Ares
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
654MO - A phase II prospective trial of frontline cabozantinib in metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2)
Presenter: Giuseppe Procopio
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
656MO - Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC)
Presenter: David McDermott
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA19 - A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (mBC) (DESIREE)
Presenter: Sibylle Loibl
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
388MO - Tumor budding, an important prognostic factor in stage III colon cancer patients treated with oxaliplatin-based chemotherapy
Presenter: Debora Basile
Session: Mini oral session - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast